Fernando J Martinez, Klaus F Rabe, Peter M A Calverley, Leonardo M Fabbri, Sanjay Sethi, Emilio Pizzichini, Andrew McIvor, Antonio Anzueto, Vijay K T Alagappan, Shahid Siddiqui, Colin Reisner, Sofia Zetterstrand, Jonas Román, Debasree Purkayastha, Nitin Bagul, Stephen I Rennard
RATIONALE: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations. Further characterization of patients most likely to benefit is warranted. OBJECTIVES: Define characteristics that most robustly identify patients who derive greatest exacerbation risk reduction with roflumilast. METHODS: Predefined, pooled analyses of REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment; NCT01329029) and RE2 SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy; NCT01443845) multicenter, randomized, double-blind, placebo-controlled studies...
November 15, 2018: American Journal of Respiratory and Critical Care Medicine
Thomas M Ormiston, Shelley R Salpeter
Beta-adrenergic blocking agents, or beta-blockers, are indicated in the management of angina pectoris, myocardial infarction, hypertension, congestive heart failure (CHF), cardiac arrhythmias, and thyrotoxicosis, and are given to reduce perioperative complications. Despite clear evidence that they reduce morbidity and mortality, clinicians are often hesitant to administer them for fear of adverse reactions. Over the past several years, many of the contraindications traditionally listed for betablockers have been questioned and disproved...
2003: Heart Failure Monitor
Morven Wilkie, Simon Finch, Stuart Schembri
Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled corticosteroids (ICS) in patients with severe airflow limitation or those at high risk of exacerbations. This recommendation is based on evidence demonstrating that ICS, especially when prescribed in fixed-dose combinations (FDC) with long-acting β2 agonists (LABA), improve quality of life (QoL), decrease exacerbations and hospitalisations, and have been associated with a trend towards a reduction in all-cause mortality. Audit shows that routine prescribing practice frequently uses inhaler therapies outside current guidelines recommendations; severe to very severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD patients are prescribed an ICS, with significant numbers given ICS/LABA as first-line maintenance therapy...
2015: COPD
Ian D Pavord, Paul W Jones, Pierre-Régis Burgel, Klaus F Rabe
Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient's condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated...
2016: International Journal of Chronic Obstructive Pulmonary Disease
David H Au
No abstract text is available yet for this article.
May 1, 2016: JAMA Internal Medicine
Peter J Barnes
The recognition that there are some patients with features of asthma and chronic obstructive pulmonary disease (COPD) has highlighted the need to develop more specific treatments for these clinical phenotypes. Some patients with COPD have predominantly eosinophilic inflammation and might respond to high doses of inhaled corticosteroids and newly developed specific antieosinophil therapies, including blocking antibodies against IL-5, IL-13, IL-33, and thymic stromal lymphopoietin, as well as oral chemoattractant receptor-homologous molecule expressed on TH2 cells antagonists...
September 2015: Journal of Allergy and Clinical Immunology
Peter K Lindenauer, Mihaela S Stefan, Meng-Shiou Shieh, Penelope S Pekow, Michael B Rothberg, Nicholas S Hill
IMPORTANCE: Small clinical trials have shown that noninvasive ventilation (NIV) is efficacious in reducing the need for intubation and improving short-term survival among patients with severe exacerbations of chronic obstructive pulmonary disease (COPD). Little is known, however, about the effectiveness of NIV in routine clinical practice. OBJECTIVE: To compare the outcomes of patients with COPD treated with NIV to those treated with invasive mechanical ventilation (IMV)...
December 2014: JAMA Internal Medicine
Stephen I Rennard, David C Dale, James F Donohue, Frank Kanniess, Helgo Magnussen, E Rand Sutherland, Henrik Watz, Susan Lu, Paul Stryszak, Elizabeth Rosenberg, Heribert Staudinger
RATIONALE: An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD). OBJECTIVES: To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD. METHODS: This 6-month, double-blind study randomized patients with moderate to severe COPD (already on standard therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo...
May 1, 2015: American Journal of Respiratory and Critical Care Medicine
Laura M Paulin, Gregory B Diette, Paul D Blanc, Nirupama Putcha, Mark D Eisner, Richard E Kanner, Andrew J Belli, Stephanie Christenson, Donald P Tashkin, MeiLan Han, R Graham Barr, Nadia N Hansel
RATIONALE: Links between occupational exposures and morbidity in individuals with established chronic obstructive pulmonary disease (COPD) remain unclear. OBJECTIVES: To determine the impact of occupational exposures on COPD morbidity. METHODS: A job exposure matrix (JEM) determined occupational exposure likelihood based on longest job in current/former smokers (n = 1,075) recruited as part of the Subpopulations and Intermediate Outcomes in COPD Study, of whom 721 had established COPD...
March 1, 2015: American Journal of Respiratory and Critical Care Medicine
Stefano Nardini, Isabella Annesi-Maesano, Mario Del Donno, Maurizio Delucchi, Germano Bettoncelli, Vincenzo Lamberti, Carlo Patera, Mario Polverino, Antonio Russo, Carlo Santoriello, Patrizio Soverina
Respiratory diseases in Italy already now represent an emergency (they are the 3(rd) ranking cause of death in the world, and the 2(nd) if Lung cancer is included). In countries similar to our own, they result as the principal cause for a visit to the general practitioner (GP) and the second main cause after injury for recourse to Emergency Care. Their frequency is probably higher than estimated (given that respiratory diseases are currently underdiagnosed). The trend is towards a further increase due to epidemiologic and demographic factors (foremost amongst which are the widespread diffusion of cigarette smoking, the increasing mean age of the general population, immigration, and pollution)...
2014: Multidisciplinary Respiratory Medicine
Daiana Stolz, Anja Meyer, Janko Rakic, Lucas Boeck, Andreas Scherr, Michael Tamm
Chronic obstructive pulmonary disease (COPD) is a complex disease with various phenotypes. The simultaneous determination of multiple biomarkers reflecting different pathobiological pathways could be useful in identifying individuals with an increased risk of death. We derived and validated a combination of three biomarkers (adrenomedullin, arginine vasopressin and atrial natriuretic peptide), assessed in plasma samples of 385 patients, to estimate mortality risk in stable COPD. Biomarkers were analysed in combination and defined as high or low...
December 2014: European Respiratory Journal
Amany F Elbehairy, Natya Raghavan, Sicheng Cheng, Ling Yang, Katherine A Webb, J Alberto Neder, Jordan A Guenette, Mahmoud I Mahmoud, Denis E O'Donnell
BACKGROUND: Smokers with persistent cough and sputum production (chronic bronchitis [CB]) represent a distinct clinical phenotype, consistently linked to negative clinical outcomes. However, the mechanistic link between physiologic impairment, dyspnea, and exercise intolerance in CB has not been studied, particularly in those with mild airway obstruction. We, therefore, compared physiologic abnormalities during rest and exercise in CB to those in patients without symptoms of mucus hypersecretion (non-CB) but with similar mild airway obstruction...
May 2015: Chest
Anouk W Vaes, Judith Garcia-Aymerich, Jacob L Marott, Marta Benet, Miriam T J Groenen, Peter Schnohr, Frits M E Franssen, Jørgen Vestbo, Emiel F M Wouters, Peter Lange, Martijn A Spruit
Little is known about changes in physical activity in subjects with chronic obstructive pulmonary disease (COPD) and its impact on mortality. Therefore, we aimed to study changes in physical activity in subjects with and without COPD and the impact of physical activity on mortality risk. Subjects from the Copenhagen City Heart Study with at least two consecutive examinations were selected. Each examination included a self-administered questionnaire and clinical examination. 1270 COPD subjects and 8734 subjects without COPD (forced expiratory volume in 1 s 67±18 and 91±15% predicted, respectively) were included...
November 2014: European Respiratory Journal
Hana Müllerova, Diego J Maselli, Nicholas Locantore, Jørgen Vestbo, John R Hurst, Jadwiga A Wedzicha, Per Bakke, Alvar Agusti, Antonio Anzueto
OBJECTIVE: Exacerbations of COPD requiring hospital admission have important clinical and societal implications. We sought to investigate the incidence, recurrence, risk factors, and mortality of patients with COPD exacerbations requiring hospital admission compared with those without hospital admission during 3-year follow-up. Patients with COPD (N = 2,138) were identified from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort...
April 2015: Chest
Fernando J Martinez, Meilan K Han, Adin-Cristian Andrei, Robert Wise, Susan Murray, Jeffrey L Curtis, Alice Sternberg, Gerard Criner, Steven E Gay, John Reilly, Barry Make, Andrew L Ries, Frank Sciurba, Gail Weinmann, Zab Mosenifar, Malcolm DeCamp, Alfred P Fishman, Bartolome R Celli
RATIONALE: The predictive value of longitudinal change in BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index has received limited attention. We hypothesized that decrease in a modified BODE (mBODE) would predict survival in National Emphysema Treatment Trial (NETT) patients. OBJECTIVES: To determine how the mBODE score changes in patients with lung volume reduction surgery versus medical therapy and correlations with survival. METHODS: Clinical data were recorded using standardized instruments...
September 1, 2008: American Journal of Respiratory and Critical Care Medicine
Danilo C Berton, Michel Reis, Ana Cristina B Siqueira, Adriano C Barroco, Luciana S Takara, Daniela M Bravo, Solange Andreoni, J Alberto Neder
BACKGROUND: It is currently unclear whether the additive effects of a long-acting beta(2)-agonist (LABA) and the antimuscarinic tiotropium bromide (TIO) on resting lung function are translated into lower operating lung volumes and improved exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). METHODS: On a double-blind and cross-over study, 33 patients (FEV(1) = 47.4 +/- 12.9% predicted) were randomly allocated to 2-wk formoterol fumarate 12 microg twice-daily (FOR) plus TIO 18 microg once-daily or FOR plus placebo (PLA)...
September 2010: Respiratory Medicine
Michelle Mocarski, Wenyi Wang, Shawn Sun, Mona Khalid, Ronald Aubert, Shailja Dixit
COPD TreatmentSESSION TYPE: Original Investigation SlidePRESENTED ON: Sunday, October 26, 2014 at 01:30 PM - 03:00 PMPURPOSE: GOLD guidelines recommend use of long-acting muscarinic antagonist (LAMA) monotherapy as an early treatment option for patients with COPD. However, some patients initiate free combination therapy of LAMA and long-acting beta agonist (LABA) while still in the early stages of COPD. This study aims to identify treatment outcomes and costs associated with LAMA+LABA use in patients with predominantly low to moderate complexity COPD, as defined by a claims based algorithm...
October 1, 2014: Chest
Marc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church
BACKGROUND: Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease (COPD). We aimed to compare the efficacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC monotherapy, or VI monotherapy in patients with moderate to very severe COPD. METHODS: In two multicentre, randomised, blinded, double-dummy, parallel-group, active-controlled trials, eligible patients (current or former smokers aged 40 years or older with an established clinical history of COPD) were randomly assigned in 1:1:1:1 ratio to UMEC 125 μg plus VI 25 μg, UMEC 62·5 μg plus VI 25 μg, TIO 18 μg, and either VI 25 μg (study 1) or UMEC 125 μg (study 2)...
June 2014: Lancet Respiratory Medicine
Robert M Kaplan, Qiankun Sun, Andrew L Ries
BACKGROUND: Surgical and medical treatments for emphysema may affect both quality and quantity of life. The purpose of this article is to report outcomes from the National Emphysema Treatment Trial (NETT) using an index that combines quality and quantity of life. METHODS: This was a prospective randomized clinical trial. Following pulmonary rehabilitation, 1,218 patients with severe emphysema were randomly assigned to maximal medical therapy or to lung volume reduction surgery (LVRS)...
February 2015: Chest
Andrea S Gershon, Michael A Campitelli, Ruth Croxford, Matthew B Stanbrook, Teresa To, Ross Upshur, Anne L Stephenson, Thérèse A Stukel
IMPORTANCE: Chronic obstructive pulmonary disease (COPD), a manageable respiratory condition, is the third leading cause of death worldwide. Knowing which prescription medications are the most effective in improving health outcomes for people with COPD is essential to maximizing health outcomes. OBJECTIVE: To estimate the long-term benefits of combination long-acting β-agonists (LABAs) and inhaled corticosteroids compared with LABAs alone in a real-world setting...
September 17, 2014: JAMA
2014-10-23 14:56:51
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.